Telomir Pharmaceuticals Files 8-K
Ticker: TELO · Form: 8-K · Filed: Sep 3, 2024 · CIK: 1971532
Sentiment: neutral
Topics: 8-K, filing, corporate-event
TL;DR
Telomir filed an 8-K, nothing major to see here yet.
AI Summary
Telomir Pharmaceuticals, Inc. filed an 8-K on September 3, 2024, reporting an "Other Events" item. The filing does not contain specific details about the event, dollar amounts, or new developments beyond the standard reporting requirements.
Why It Matters
This filing indicates a standard corporate event reporting requirement for Telomir Pharmaceuticals, Inc. It does not provide new financial information or strategic updates.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not disclose any new material risks or significant financial changes.
Key Players & Entities
- Telomir Pharmaceuticals, Inc. (company) — Registrant
- September 3, 2024 (date) — Date of earliest event reported
- Florida (location) — State of Incorporation
- Miami, FL (location) — Principal Executive Offices
FAQ
What specific event is being reported under 'Other Events' in this 8-K filing?
The filing does not specify the nature of the 'Other Events' beyond the general category.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on September 3, 2024.
What is the state of incorporation for Telomir Pharmaceuticals, Inc.?
Telomir Pharmaceuticals, Inc. is incorporated in Florida.
What is the principal executive office address for Telomir Pharmaceuticals, Inc.?
The principal executive office is located at 100 SE 2nd St, Suite 2000 #1009, Miami, FL 33131.
Does this 8-K filing contain any financial updates or material business changes?
No, this filing is categorized under 'Other Events' and does not provide specific financial updates or details on material business changes.
Filing Stats: 782 words · 3 min read · ~3 pages · Grade level 14.1 · Accepted 2024-09-03 16:37:19
Filing Documents
- form8-k.htm (8-K) — 41KB
- 0001493152-24-034831.txt ( ) — 261KB
- telo-20240903.xsd (EX-101.SCH) — 3KB
- telo-20240903_def.xml (EX-101.DEF) — 29KB
- telo-20240903_lab.xml (EX-101.LAB) — 35KB
- telo-20240903_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TELOMIR PHARMACEUTICALS, INC. Date: September 3, 2024 By: /s/ Erez Aminov Erez Aminov Chief Executive Officer